The iLine F microscope to close, automate, and control the cells expansion

In the field of immunotherapy, the need for continuous measurement of critical quality attributes (CQAs) of the cell product is the next frontier. The iLine F microscope to close, automate, and control the cells expansion to ensure a real-time, in-line monitoring of CQAs, as explained in this article from CCRM:

Free Webinar: Let's Go Viral!

Free Webinar: Let's Go Viral

Real-time and Label free Monitoring of Viral Infection Kinetics in Suspension Cultures with our Automated, In-line iLine F.

The bioprocess industry has been familiarised with newer techniques and robust scientific applications to assist in process analytics and a more streamlined process. We invite you to learn more about Differential Digital Holographic Microscopy (DDHM) at our upcoming webinar that will focus on in-line, automated capabilities for upstream process development and real time viral infection kinetics monitoring using Ovizio’s iLine F.


Wednesday July 18
16h00-16h30 CEST
10h00-10h00 am EDT
7h00-7h30 am PDT
Interested? Register on:

Ovizio Imaging Systems appoints Dr. Emilie Viey as Chief Executive Officer

Ovizio has the pleasure to announce the appointment of Dr. Emilie VIEY as its new CEO. Please check our press release


Automated, In-Line Cell Culture Monitoring of CAR-T Cells in a Closed Loop System

Registration for our interactive Webinar on August 22, 2018 is now open!

Follow the link below to see the agenda:

Knowledge for Growth, Ghent, May 17

Ovizio will be presenting a poster at Knowledge for Growth. You can find Jan Van Hauwermeiren at poster 19: Quantitative Phase Imaging: from cell counting to continuous monitoring of viral load in a bioreactor.

Free Lunch Seminar

The bioprocess industry has been introduced to newer techniques and robust scientific applications to assist in process analytics and a more streamlined process.  We invite you to learn more about Differential Digital Holographic Technology (DDHM) at our upcoming seminar that will focus on in-line, automated capabilities for upstream process development and cell culture monitoring.

Seminar Topics:

  • In-line and automated bioprocess capabilities
  • New developments in infection kinetics detection with machine learning software
  • Other advanced applications for cell culture and bioprocesses
  • Lunch will be served!

Register HERE


Label-free, high-throughput detection of P. falciparum infection in sphered erythrocytes with digital holographic microscopy

Matthias Ugele, Markus Weniger, Maria Leidenberger, Yiwei Huang, Michael Bassler, Oliver Friedrich, Barbara Kappes, Oliver Hayden, Lukas Richter
In-Vitro DX & Bioscience, Department of Strategy and Innovation, Siemens Healthcare GmbH, Günther-Scharowsky-Str. 1, 91058 Erlangen, Germany.

Differential digital holographic microscopy, in combination with two-dimensional hydrodynamic focusing allowed dye-free detection of P. falciparum infection in sphered erythrocytes, with a parasitemia detection limit of 0.01%. Moreover, it even shows potential for future discrimination of malaria species.

Prof. Dr. Oliver Hayden, MBA, Heinz-Nixdorf-Chair of Biomedical Electronics at TranslaTUM

Dear Professor, could you please introduce yourself and your research briefly?

“I have a rather unusual career as a biochemist, who enjoys to jump between academic and industrial research, basic and applied sciences. Last year, I joined TU Munich leaving Siemens Healthcare to become part of a unique “cultural experiment” between pre-/clinical research and engineering. My Chair is located in the TranslaTUM at the campus of University Hospital Klinikum rechts der Isar. Our vision is to mediate translational research projects between clinicians, basic scientists, and entrepreneurial partners. The focus of my own research is the development of workflows for precise cell function diagnostics on various time scales.”

What made you aware of Ovizio technology?

“When working at Siemens we explored different technologies in the space of quantitative phase microscopy. Ovizio was the one with the highest potential and was a match to our intended use.”

How did you envision the integration of Ovizio microscope with your existing process?

“Ovizio’s technology is an enabler for our method development, which covers optics, microfluidics, and most importantly workflow integration. We are looking forward to cooperating with Ovizio and explore the rich opportunities to improve automated cell diagnostics.”

Can you comment on the results you have generated and how the technology has helped you improve your process?

“I have been the PI (Principal Investigator) at Siemens to explore imaging modalities for cell diagnostics. In two publications my team could demonstrate that leukocyte differentiation does not require any sample preparation. In fact, the contrast of untouched leukocytes with our customized Ovizio microscope is high enough to discriminate a large variety of benign and malign cells which allowed us to even discriminate leukemia. The data quality is high enough that automated analysis of pathological conditions can be envisioned.“

According to you, what are the key benefits of the technology? And what were the challenges you have faced during integration?

“Critical for any clinical application is robustness of the method. With Ovizio’s setup, we learned that phase microscopy can be very reliable. Furthermore, workflow integration for a reference database remains challenging for a translational project.  Such an effort requires access to thousands of clinical samples and close cooperation between engineering and clinicians. Such an environment is offered by TranslaTUM which was also the main motivation to move to TU Munich.”

According to your experience, what would be the next step for Ovizio? How could we further improve the technology? What other benefit would you be looking for?

“Every team with a platform technology faces the same challenges in identifying and prioritizing the right market segment to focus on. I believe stand-alone microscopes are probably less attractive due to market forces. Ovizio is a rising star with a passionate team and a first unique product for bioreactor control moving its portfolio beyond traditional markets. I believe Ovizio still has time to learn what value chain share matches and which apps and workflows make a true difference. Obviously, image analytics is one asset. The problem is how to get to high-quality data with content information. For the MedTech industry, such a scenario requires close public-private partnership which could be beneficial for engineering and clinical utility.”


Cell Therapy Manufacturing and Gene Therapy Congress in Amsterdam

Ovizio will attend the Cell Therapy Manufacturing and Gene Therapy Congress in Amsterdam, this week !

To see the agenda of the week, klik here:

Bioprocessing Summit Europe, Lisbon, March 20-22

Ovizio will have a booth during the first Bioprocessing Summit Europe, held in Lisbon.

On Wednesday we will present the latest advancements of our technology.

More info can be found here

We can offer you a discount code for your registration at the conference. Please contact us at

BioProcessing Days 2018, Recklinghausen, Feb 19-21

Ovizio will be present together with our German distributor I&L Biosystems during the BioProcessingDays at Recklinghausen.

More info can be found here: BioProcessingDays 2018